Risk factors for losing hepatitis B virus surface antibody in patients with HBV surface antigen negative/surface antibody positive serostatus receiving biologic disease-modifying anti-rheumatic drugs: a nested case-control study

Hepatitis B virus (HBV) reactivation consequent to immunosuppressive therapy is an increasingly prevalent problem with serious clinical implications. Treatment with biologic agents conduces to the loss of protective antibody to HBV surface antigen (anti-HBs), which significantly increases the risk o...

Full description

Saved in:
Bibliographic Details
Published in:Advances in rheumatology (London, England) England), 2021-04, Vol.61 (1), p.22-22, Article 22
Main Authors: Hung, Ming-Hui, Tien, Ya-Chih, Chiu, Ying-Ming
Format: Article
Language:English
Subjects:
Ankylosing spondylitis
Anti-HBs loss
Antibodies
Antigens
Antirheumatic Agents - therapeutic use
Autoimmune diseases
Biologic disease-modifying anti-rheumatic drug (DMARD)
Biological Products - therapeutic use
Case-Control Studies
Chronic kidney disease
Deoxyribonucleic acid
Diabetes
Diabetes mellitus
DNA
Drug development
Drug dosages
HBV surface-antigen negative/surface antibody positive (HBsAg−/anti-HBs+)
Hepatitis B
Hepatitis B surface antigen
Hepatitis B Surface Antigens - blood
Hepatitis B virus (HBV)
Hepatitis B virus - immunology
Humans
Immunosuppressive agents
Kidney diseases
Laboratories
Liver diseases
Multivariate analysis
Patients
Prophylaxis
Prospective Studies
Psoriasis
Psoriatic arthritis
Rheumatic diseases
Rheumatic Diseases - blood
Rheumatic Diseases - drug therapy
Rheumatoid arthritis
RHEUMATOLOGY
Risk Factors
Software
Standard deviation
Tumor necrosis factor-TNF
Ultrasonic imaging
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hepatitis B virus (HBV) reactivation consequent to immunosuppressive therapy is an increasingly prevalent problem with serious clinical implications. Treatment with biologic agents conduces to the loss of protective antibody to HBV surface antigen (anti-HBs), which significantly increases the risk of HBV reactivation. Hence, we investigated the risk factors for losing anti-HBs in patients with rheumatic diseases and HBV surface antigen negative/anti-HBs positive (HBsAg-/anti-HBs+) serostatus during treatment with biologic disease-modifying anti-rheumatic drugs (DMARDs). Using a nested case-control design, we prospectively enrolled patients with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis/psoriasis, or juvenile idiopathic arthritis, who were treated with biologic DMARDs at Changhua Christian Hospital, Taiwan, from January 2013 to June 2019 and had HBsAg-/anti-HBs+ serostatus; the analytic sample excluded all patients with HBsAg+ or anti-HBs- serostatus. Anti-HBs titers were monitored 6-monthly and cases were defined as anti-HBs
ISSN:2523-3106
2523-3106
DOI:10.1186/s42358-021-00173-9